Importantly, numerous immune-related adverse events (irAEs) have been reported in patients with NSCLC treated with PD-1 or PD-L1 inhibitors, including pneumonitis, thyroiditis, and dermatitis [9]. Here, CD274 is linked to non-small cell lung carcinoma.